Wegovy Pill vs. Injection: How the Oral and Weekly Versions Compare

For four years the only way to take semaglutide for weight loss was a weekly injection. That changed on December 23, 2025, when the FDA approved a 25 mg tablet under the same Wegovy brand name. It reached US pharmacies in January 2026.

It is the same molecule, from the same manufacturer, sharing a single prescribing label. The differences are not really about the drug — they are about the routine it asks of you, and about who each version is approved to treat.

The short version

How much weight do people lose on each?

In OASIS-4, the trial behind the tablet's approval, participants who stayed on treatment lost a mean 16.6% of body weight, and about one in three lost 20% or more. In STEP 1, the registration trial for the 2.4 mg injection, mean weight loss was 14.9% at 68 weeks.

Resist the urge to read that as the pill winning. These were separate trials, run at different times, in different populations, with different analysis methods — the 16.6% figure describes people who adhered to treatment, which is a more favourable measure than the trial-wide average. There is no head-to-head study. The fair summary is that the two deliver weight loss in the same broad range.

The daily routine is the real difference

This is where most people will actually decide, and it is the part the headlines skip. Semaglutide is a large peptide that is poorly absorbed from the gut, so the tablet only works under strict conditions. The label is specific:

• Take it in the morning on an empty stomach.
• Swallow it with no more than 4 ounces of water — and no other liquid. Not coffee, not juice.
• Swallow it whole. Do not split, crush, chew or dissolve it.
• Then wait at least 30 minutes before eating, drinking anything else, or taking any other oral medication.
• Never more than one tablet a day.

The injection has none of this. The label says once weekly, same day each week, any time of day, with or without meals, into the abdomen, thigh or upper arm — and you can change the day and the site without adjusting the dose.

So the honest trade is this: the injection costs you a needle once a week. The tablet costs you a protected half-hour every morning, including weekends, holidays and travel days, and a 30-minute delay on your coffee and any other morning medication. People who take thyroid medication on an empty stomach will recognise the problem immediately.

How the doses step up

Both versions titrate slowly to limit nausea, but on different clocks.

If a dose is not tolerated during escalation, the label says to consider delaying the step up rather than pushing through.

What each one is approved to treat

This asymmetry gets almost no coverage, and for some people it settles the question outright. Both versions are approved to reduce major adverse cardiovascular events in adults with established cardiovascular disease and either obesity or overweight, and both are approved for weight reduction in adults.

But the injection alone is approved for two more things: weight reduction in adolescents aged 12 and older with obesity, and the treatment of noncirrhotic MASH with moderate to advanced liver fibrosis, under accelerated approval. If either applies to you, the tablet is not an option.

Can you switch between them?

Yes, and the label gives the protocol rather than leaving it to guesswork.

• Injection to tablet: patients on 2.4 mg injection may switch to 25 mg tablets. Start the tablets one week after the last injection.
• Tablet to injection: patients on 25 mg tablets may switch to the injection.
• If the 25 mg tablet is not tolerated, the label specifically suggests considering the 1.7 mg weekly injection instead — a lower-exposure route rather than abandoning treatment.

Missed doses are handled differently

With the tablet, skip the missed dose entirely and take the next one the following day. With the injection, take it as soon as possible if the next scheduled dose is more than two days away; if it is less than two days away, skip it and resume on your usual day. If two or more consecutive weekly doses are missed, the label notes you may need to restart the escalation schedule — which is its own argument for not losing track.

What they cost

The tablet carries a list price around $1,349 a month, which is in the same territory as the injection and is not what most people pay. Manufacturer cash-pay programmes, insurance coverage and dose all move the real number substantially. Our GLP-1 Cost Index tracks what each route actually costs at maintenance, which is the number that matters once you are past the first few months.

Which one should you ask about?

Neither is better in the abstract. The useful question is which failure mode you are more likely to hit.

• The tablet suits you if needles are a genuine barrier, if you already have a stable empty-stomach morning routine, or if you travel somewhere refrigeration is awkward.
• The injection suits you if your mornings are unpredictable, if you take other oral medication on waking, if you would rather think about treatment once a week than every day, or if you are an adolescent or being treated for MASH.

One more thing worth raising with a clinician: both carry the same boxed warning for thyroid C-cell tumours, and the label advises against combining either with any other semaglutide product or any other GLP-1 receptor agonist.